Celebrex History - Celecoxib History
Information on the history of the COX-2 selective inhibitor drug Celebrex, generic drug name celecoxib.
05/29/2004 Celebrex History: Is Celebrex Safest Anti-Inflammatory?
05/29/2004, Celebrex appears to have lower risk of congestive heart failure, according to Canadian study.
05/29/2004, Celebrex appears to have lower risk of congestive heart failure, according to Canadian study.
03/02/2002 Celebrex History: Comparison: Celebrex And Vioxx
03/02/2002, An overview of the similarities and differences between the popular COX-2 inhibitors prescribed for the treatment of arthritis.
03/02/2002, An overview of the similarities and differences between the popular COX-2 inhibitors prescribed for the treatment of arthritis.
Celebrex And Vioxx Issue Rival Reports
Pharmacia and Merck, the respective makers of Celebrex and Vioxx, both reported study results which claim their drug is the better choice for the treatment of osteoarthritis.
Pharmacia and Merck, the respective makers of Celebrex and Vioxx, both reported study results which claim their drug is the better choice for the treatment of osteoarthritis.
Celebrex And Vioxx Set To Battle
Celebrex and Vioxx compete as new drugs for the treatment of arthritis.
Celebrex and Vioxx compete as new drugs for the treatment of arthritis.
05/14/2001 Celebrex History: Second, Replicate Study Favors Celebrex
05/14/2001, study compares Celebrex and Vioxx and their cardiovascular side effects.
05/14/2001, study compares Celebrex and Vioxx and their cardiovascular side effects.
02/08/2001 Celebrex History: FDA Advised On Celebrex & Vioxx
02/08/2001, FDA Arthritis Advisory Committee met to review study results and to assess if either Celebrex or Vioxx should have warnings on their label reduced or any changes made to the prescribing information.
02/08/2001, FDA Arthritis Advisory Committee met to review study results and to assess if either Celebrex or Vioxx should have warnings on their label reduced or any changes made to the prescribing information.
06/22/2000 Celebrex History: Celebrex And Vioxx Issue Rival Reports
06/22/2000, Pharmacia and Merck, the respective makers of Celebrex and Vioxx, both reported study results which claim their drug is the better choice for the treatment of osteoarthritis.
06/22/2000, Pharmacia and Merck, the respective makers of Celebrex and Vioxx, both reported study results which claim their drug is the better choice for the treatment of osteoarthritis.
Celebrex Causes Concern
Two reports are causing concern over Celebrex.
Two reports are causing concern over Celebrex.
02/20/2000 Celebrex History: Platelets Not Disrupted By Celebrex
02/16/2000, Study results show that Celebrex does not interfere with normal platelet function.
02/16/2000, Study results show that Celebrex does not interfere with normal platelet function.
05/09/1999 Celebrex History: Celebrex Rebounds After WSJ Report
05/09/1999, Follow-up analysis indicates concern over Celebrex report was overblown.
05/09/1999, Follow-up analysis indicates concern over Celebrex report was overblown.
04/21/1999 Celebrex History: Celebrex Causes Concern
04/21/1999, Reports in the news about Celebrex cause concern, the FDA stresses no need for alarm.
04/21/1999, Reports in the news about Celebrex cause concern, the FDA stresses no need for alarm.
Comparison: Celebrex And Vioxx
An overview of the similarities and differences between the new popular COX-2 inhibitors prescribed for the treatment of arthritis.
An overview of the similarities and differences between the new popular COX-2 inhibitors prescribed for the treatment of arthritis.
01/13/1999 Celebrex History: Celebrex And Vioxx Set To Battle
01/13/1999, Manufacturers of Celebrex and Vioxx are competing for the majority of the market trying out the new COX-2 inhibitors.
01/13/1999, Manufacturers of Celebrex and Vioxx are competing for the majority of the market trying out the new COX-2 inhibitors.
FDA Advised On Celebrex & Vioxx
On February 7th and 8th (2001), the FDA Arthritis Advisory Committee met to review study results and to assess if either Celebrex or Vioxx should have warnings on their label reduced or any changes made to the prescribing information.
On February 7th and 8th (2001), the FDA Arthritis Advisory Committee met to review study results and to assess if either Celebrex or Vioxx should have warnings on their label reduced or any changes made to the prescribing information.
01/03/1999 Celebrex History: Celebrex (Celecoxib) Approved By FDA
01/03/1999, FDA approves Celebrex (celecoxib) for osteoarthritis and rheumatoid arthritis.
01/03/1999, FDA approves Celebrex (celecoxib) for osteoarthritis and rheumatoid arthritis.
Platelets Not Disrupted By Celebrex
Recent study results show that the arthritis medication Celebrex does not interfere with normal platelet function.
Recent study results show that the arthritis medication Celebrex does not interfere with normal platelet function.
12/02/1998 Celebrex History: Celebrex Recommended For Approval
12/02/1998, FDA advisory panel unanimously recommends the approval of Celebrex for osteoarthritis and rheumatoid arthritis.
12/02/1998, FDA advisory panel unanimously recommends the approval of Celebrex for osteoarthritis and rheumatoid arthritis.
06/23/1998 Celebrex History: Super Aspirins: Superior Arthritis Drugs
06/23/1998, A new class of drugs, COX-2 inhibitors, is being developed which will strengthen the arsenal used to treat arthritis.
06/23/1998, A new class of drugs, COX-2 inhibitors, is being developed which will strengthen the arsenal used to treat arthritis.
Second Study Favors Celebrex
A study sponsored by Pharmacia, the maker of Celebrex, confirmed that more patients taking Vioxx exhibited "statistically significant and clinically important" increases in systolic blood pressure and edema than patients taking Celebrex. Merck, the maker of Vioxx, is disputing the findings.
A study sponsored by Pharmacia, the maker of Celebrex, confirmed that more patients taking Vioxx exhibited "statistically significant and clinically important" increases in systolic blood pressure and edema than patients taking Celebrex. Merck, the maker of Vioxx, is disputing the findings.